Differential inhibitory potencies and mechanisms of the type I ribosome inactivating protein marmorin on estrogen receptor (ER)-positive and ER-negative breast cancer cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 5, 2013, Pages 987-996

  Pan, Wen Liang ^a   Wong, Jack Ho ^a   Fang, Evandro Fei ^b   Chan, Yau Sang ^a   Ye, Xiu Juan ^c   Ng, Tzi Bun ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c FUJIAN AGRICULTURE AND FORESTRY UNIVERSITY   (China)

Author keywords

Apoptosis; Breast cancer; Endoplasmic reticulum stress; Estrogen receptor ; Marmorin; Ribosome inactivating protein

Indexed keywords

CASPASE 12; CASPASE 8; CASPASE 9; DEATH RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; INOSITOL; INOSITOL REQUIRING PROTEIN 1 ALPHA; MARMORIN; PROTEIN KINASE; PROTEIN KINASE RNA ACTIVATED LIKE ENDOPLASMIC RETICULUM KINASE; RIBOSOME INACTIVATING PROTEIN 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ATTENUATION; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HYPSIZIGUS MARMOREUS; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MUSHROOM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

APOPTOSIS; BREAST NEOPLASMS; EIF-2 KINASE; ENDOPLASMIC RETICULUM STRESS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MITOCHONDRIA; NEOPLASMS, HORMONE-DEPENDENT; UP-REGULATION;

EID: 84874373257     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.12.013     Document Type: Article

References (43)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Shaaban A.M., Sloane J.P., West C.R., Foster C.S. Breast cancer risk in usual ductal hyperplasia is defined by estrogen. Am. J. Pathol. 2002, 160:597-604.
3. Shoker B.S., Jarvis C., Sibson D.R., Walker C., Sloane J.P. Oestrogen receptor expression in the normal and pre-cancerous breast. J. Pathol. 1999, 188:237-244.
4. Levin E.R. Integration of the extranuclear and nuclear actions of estrogen. Mol. Endocrinol. 2005, 19:1951-1959.
5. Kim R., Kaneko M., Arihiro K., Emi M., Tanabe K., Murakami S., Osaki A., Inai K. Extranuclear expression of hormone receptors in primary breast cancer. Ann. Oncol. 2006, 17:1213-1220.
6. Shao W., Brown M. Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res. 2004, 6:39-52.
7. Peverali F.A., Ramqvist T., Saffrich R., Pepperkok R., Barone M.V., Philipson L. Regulation of G1 progression by E2A and Id helix-loop-helix proteins. EMBO J. 1994, 13:4291-4301.
8. Liu W.S., Swetzig W.M., Medisetty R., Das G.M. Estrogen-mediated upregulation of Noxa Is associated with cell cycle progression in estrogen receptor-positive breast cancer cells. PLoS One 2011, 6.
9. Yang Q., Sakurai T., Jing X., Utsunomiya H., Shan L., Nakamura Y., Nakamura M., Oura S., Suzuma T., Yoshimura G., Umemura T., Kokawa Y., Kakudo K. Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma. Pathol. Int. 1999, 49:775-780.
10. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., Orntoft T., Lukas J., Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
11. Gorgoulis V.G., Vassiliou L.V.F., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., DiTullio R.A., Kastrinakis N.G., Levy B., Kletsas D., Yoneta A., Herlyn M., Kittas C., Halazonetis T.D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
12. Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 2011, 62:233-247.
13. Olsnes S. The history of ricin, abrin and related toxins. Toxicon 2004, 44:361-370.
14. Stirpe F. Ribosome-inactivating proteins - Preface. Mini Rev. Med. Chem. 2004, 4.
15. Brigotti M., Accorsi P., Carnicelli D., Rizzi S., Vara A.G., Montanaro L., Sperti S. Shiga toxin 1: damage to DNA in vitro. Toxicon 2001, 39:341-348.
16. Girbes T., Ferreras J.M., Arias F.J., Stirpe F. Description, distribution, activity and phylogenetic relationship of ribosome-inactivating proteins in plants, fungi and bacteria. Mini Rev. Med. Chem. 2004, 4:461-476.
17. Lam S.K., Ng T.B. First simultaneous isolation of a ribosome inactivating protein and an antifungal protein from a mushroom (Lyophyllum shimeji) together with evidence for synergism of their antifungal effects. Arch. Biochem. Biophys. 2001, 393:271-280.
18. Lam S.K., Ng T.B. Hypsin, a novel thermostable ribosome-inactivating protein with antifungal and antiproliferative activities from fruiting bodies of the edible mushroom Hypsizigus marmoreus. Biochem. Biophys. Res. Commun. 2001, 285:1071-1075.
19. Wong J.H., Wang H.X., Ng T.B. Marmorin, a new ribosome inactivating protein with antiproliferative and HIV-1 reverse transcriptase inhibitory activities from the mushroom Hypsizigus marmoreus. Appl. Microbiol. Biotechnol. 2008, 81:669-674.
20. Battelli M.G. Cytotoxicity and toxicity to animals and humans of ribosome-inactivating proteins. Mini Rev. Med. Chem. 2004, 4:513-521.
21. Narayanan S., Surendranath K., Bora N., Surolia A., Karande A.A. Ribosome inactivating proteins and apoptosis. FEBS Lett. 2005, 579:1324-1331.
22. Gan Y.H., Peng S.Q., Liu H.Y. Molecular mechanism of apoptosis induced by ricin in HeLa cells. Acta Pharmacol. Sin. 2000, 21:243-248.
23. Horrix C., Raviv Z., Flescher E., Voss C., Berger M. Plant ribosome-inactivating proteins type II induce the unfolded protein response. Cell. Mol. Life Sci. 2011, 68:1269-1281.
24. Shih S.F., Wu Y.H., Hung C.H., Yang H.Y., Lin J.Y. Abrin triggers cell death by inactivating a thiol-specific antioxidant protein. J. Biol. Chem. 2001, 276:21870-21877.
25. Sikriwal D., Ghosh P., Batra J.K. Ribosome inactivating protein saporin induces apoptosis through mitochondrial cascade, independent of translation inhibition. Int. J. Biochem. Cell Biol. 2008, 40:2880-2888.
26. Xiong S.D., Yu K., Liu X.H., Yin L.H., Kirschenbaum A., Yao S., Narla G., DiFeo A., Wu J.B., Yuan Y., Ho S.M., Lam Y.W., Levine A.C. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int. J. Cancer 2009, 125:774-782.
27. Lavastre V., Pelletier M., Saller R., Hostanska K., Girard D. Mechanisms involved in spontaneous and Viscum album agglutinin-I-induced human neutrophil apoptosis: viscum album agglutinin-I accelerates the loss of antiapoptotic Mcl-1 expression and the degradation of cytoskeletal paxillin and vimentin proteins via caspases. J. Immunol. 2002, 168:1419-1427.
28. Zhang C., Gong Y., Ma H., An C., Chen D., Chen Z.L. Reactive oxygen species involved in trichosanthin-induced apoptosis of human choriocarcinoma cells. Biochem. J. 2001, 355:653-661.
29. Bolognesi A., Polito L., Tazzari P.L., Lemoli R.M., Lubelli C., Fogli M., Boon L., de Boer M., Stirpe F. In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. Br. J. Haematol. 2000, 110:351-361.
30. Fang E.F., Lin P., Wong J.H., Tsao S.W., Ng T.B. A lectin with anti-HIV-1 reverse transcriptase, antitumor, and nitric oxide inducing activities from seeds of Phaseolus vulgaris cv. extralong autumn purple bean. J. Agric. Food Chem. 2010, 58:2221-2229.
31. Fang E.F., Pan W.L., Wong J.H., Chan Y.S., Ye X.J., Ng T.B. A new Phaseolus vulgaris lectin induces selective toxicity on human liver carcinoma Hep G2 cells. Arch. Toxicol. 2011, 85:1551-1563.
32. Fang E.F., Zhang C.Z., Ng T.B., Wong J.H., Pan W.L., Ye X.J., Chan Y.S., Fong W.P. Momordica Charantia lectin, a type II ribosome inactivating protein, exhibits antitumor activity toward human nasopharyngeal carcinoma cells in vitro and in vivo. Cancer Prev. Res. (Phila.) 2012, 5:109-121.
33. Zhang K., Kaufman R.J. Signaling the unfolded protein response from the endoplasmic reticulum. J. Biol. Chem. 2004, 279:25935-25938.
34. Kaufman R.J. Orchestrating the unfolded protein response in health and disease. J. Clin. Invest. 2002, 110:1389-1398.
35. Ron D. Translational control in the endoplasmic reticulum stress response. J. Clin. Invest. 2002, 110:1383-1388.
36. Ma Y.J., Brewer J.W., Diehl J.A., Hendershot L.M. Two distinct stress signaling pathways converge upon the CHOP promoter during the mammalian unfolded protein response. J. Mol. Biol. 2002, 318:1351-1365.
37. Ingle J.N., Krook J.E., Green S.J., Kubista T.P., Everson L.K., Ahmann D.L., Chang M.N., Bisel H.F., Windschitl H.E., Twito D.I., et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J. Clin. Oncol. 1986, 4:178-185.
38. Smolnikar K. Faslodex(TM) for the treatment of breast cancer. Drugs Today (Barc.) 2001, 37:783-789.
39. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
40. Wang X.Z., Ron D. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase. Science 1996, 272:1347-1349.
41. Ohoka N., Yoshii S., Hattori T., Onozaki K., Hayashi H. TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J. 2005, 24:1243-1255.
42. Morgan L., Gee J., Pumford S., Farrow L., Finlay P., Robertson J., Ellis I., Kawakatsu H., Nicholson R., Hiscox S. Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol. Ther. 2009, 8:1550-1558.
43. Zhang W.G., Shi H.Y., Zhang M. Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins. BMC Cancer 2005, 5.